Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 280-287

  Alotte, Christine ^a,b   Martin, Amaury ^a,b   Caldarelli, Sergio A ^c   Di Giorgio, Audrey ^c   Condom, Roger ^c   Zoulim, Fabien ^a,b,d   Durantel, David ^a,b   Hantz, Olivier ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CNRS   (France)

^d Service d'Hepatologie   (France)

Author keywords

Antisense; Hepatitis C virus; IRES; JFH1 strain; Peptide nucleic acid; PNA

Indexed keywords

ALPHA2B INTERFERON; COMPLEMENTARY DNA; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PEPTIDE NUCLEIC ACID; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LYSATE; CONTROLLED STUDY; ELECTROPORATION; GENE AMPLIFICATION; GENE CONSTRUCT; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REPLICON; RETICULOCYTE; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

5' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; CELL LINE; DNA, ANTISENSE; DOWN-REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE NUCLEIC ACIDS; PROTEIN BIOSYNTHESIS; RABBITS; RETICULOCYTES; RIBOSOMES;

HEPATITIS C VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 56649103774     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.06.011     Document Type: Article

References (50)

1. Aldaz-Carroll L., Tallet B., Dausse E., Yurchenko L., and Toulmé J.J. Apical loop-internal loop interactions: a new RNA-RNA recognition motif identified through in vitro selection against RNA hairpins of the hepatitis C virus mRNA. Biochemistry 41 (2002) 5883-5893
2. Alt M., Eisenhardt S., Serwe M., Renz R., Engels J.W., and Caselmann W.H. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Eur. J. Clin. Invest. 29 (1999) 868-876
3. Alt M., Renz R., Hofschneider P.H., and Caselmann W.H. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch. Virol. 142 (1997) 589-599
4. Blight K.J., McKeating J.A., and Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76 (2002) 13001-13014
5. Branch A.D. A good antisense molecule is hard to find. Trends Biochem. Sci. 23 (1998) 45-50
6. Brown-Driver V., Eto T., Lesnik E., Anderson K.P., and Hanecak R.C. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9 (1999) 145-154
7. Caldarelli S.A., Mehiri M., Di Giorgio A., Martin A., Hantz O., Zoulim F., Terreux R., Condom R., and Patino N. A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation. Bioorg. Med. Chem. 13 (2005) 5700-5709
8. Chevaliez S., and Pawlotsky J.M. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J. Gastroenterol. 13 (2007) 2461-2466
9. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
10. Christensen L., Fitzpatrick R., Gildea B., Petersen K.H., Hansen H.F., Koch T., Egholm M., Buchardt O., Nielsen P.E., Coull J., et al. Solid-phase synthesis of peptide nucleic acids. J. Pept. Sci. 1 (1995) 175-183
11. Crooke S.T. Progress toward oligonucleotide therapeutics: pharmacodynamic properties. FASEB J. 7 (1993) 533-539
12. Crooke S.T. Progress in antisense technology. Annu. Rev. Med. 55 (2004) 61-95
13. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6 (2007) 1001-1018
14. De Francesco R., and Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 436 (2005) 953-960
15. Demidov V.V., Potaman V.N., Frank-Kamenetskii M.D., Egholm M., Buchard O., Sönnichsen S.H., and Nielsen P.E. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol. 48 (1994) 1310-1313
16. Depecker G., Patino N., Di Giorgio C., Terreux R., Cabrol-Bass D., Bailly C., Aubertin A.M., and Condom R. Cyclic PNA-based compound directed against HIV-1 TAR RNA: modelling, liquid-phase synthesis and TAR binding. Org. Biomol. Chem. 2 (2004) 74-79
17. Doyle D.F., Braasch D.A., Simmons C.G., Janowski B.A., and Corey D.R. Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length. Biochemistry 40 (2001) 53-64
18. Dutartre H., Bussetta C., Boretto J., and Canard B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob. Agents Chemother. 50 (2006) 4161-4169
19. Hanecak R., Brown-Driver V., Fox M.C., Azad R.F., Furusako S., Nozaki C., Ford C., Sasmor H., and Anderson K.P. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70 (1996) 5203-5212
20. Honda M., Beard M.R., Ping L.H., and Lemon S.M. A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. J. Virol. 73 (1999) 1165-1174
21. Honda M., Brown E.A., and Lemon S.M. Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA 2 (1996) 955-968
22. Krönke J., Kittler R., Buchholz F., Windisch M.P., Pietschmann T., Bartenschlager R., and Frese M. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. 78 (2004) 3436-3446
23. Le Pogam S., Kang H., Harris S.F., Leveque V., Giannetti A.M., Ali S., Jiang W.R., Rajyaguru S., Tavares G., Oshiro C., Hendricks T., Klumpp K., Symons J., Browner M.F., Cammack N., and Nájera I. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80 (2006) 6146-6154
24. Lima W.F., Brown-Driver V., Fox M., Hanecak R., and Bruice T.W. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272 (1997) 626-638
25. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
26. Lundin K.E., Good L., Stromberg R., Graslund A., and Smith C.I. Biological activity and biotechnological aspects of peptide nucleic acid. Adv. Genet. 56 (2006) 1-51
27. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., and Houghton M. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov. 6 (2007) 991-1000
28. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006) 1350-1359
29. McCaffrey A.P., Meuse L., Karimi M., Contag C.H., and Kay M.A. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38 (2003) 503-508
30. McHutchison J.G., Patel K., Pockros P., Nyberg L., Pianko S., Yu R.Z., Dorr F.A., and Kwoh T.J. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol. 44 (2006) 88-96
31. Mizutani T., Kato N., Hirota M., Sugiyama K., Murakami A., and Shimotohno K. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochem. Biophys. Res. Commun. 212 (1995) 906-911
32. Mo H., Lu L., Pilot-Matias T., Pithawalla R., Mondal R., Masse S., Dekhtyar T., Ng T., Koev G., Stoll V., Stewart K.D., Pratt J., Donner P., Rockway T., Maring C., and Molla A. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 49 (2005) 4305-4314
33. Moradpour D., Penin F., and Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5 (2007) 453-463
34. Nakabayashi H., Taketa K., Miyano K., Yamane T., and Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42 (1982) 3858-3863
35. Nielsen P.E., Egholm M., Berg R.H., and Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254 (1991) 1497-1500
36. Nielsen P.E., and Haaima G. Peptide nucleic acid (PNA). A DNA mimic with a pseudopeptide backbone. Chem. Soc. Rev. (1997) 73-78
37. Nulf C.J., and Corey D. Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res. 32 (2004) 3792-3798
38. Rasmussen F.W., Bendifallah N., Zachar V., Shiraishi T., Fink T., Ebbesen P., Nielsen P.E., and Koppelhus U. Evaluation of transfection protocols for unmodified and modified peptide nucleic acid (PNA) oligomers. Oligonucleotides 16 (2006) 43-57
39. Robaczewska M., Narayan R., Seigneres B., Schorr O., Thermet A., Podhajska A.J., Trepo C., Zoulim F., Nielsen P.E., and Cova L. Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). J. Hepatol. 42 (2005) 180-187
40. Seki M., and Honda Y. Phosphorothioate antisense oligodeoxynucleotides capable of inhibiting hepatitis C virus gene expression: in vitro translation assay. J. Biochem. 118 (1995) 1199-1204
41. Smith D.B., Mellor J., Jarvis L.M., Davidson F., Kolberg J., Urdea M., Yap P.L., and Simmonds P. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J. Gen. Virol. 76 (1995) 1749-1761
42. Soler M., Pellerin M., Malnou C.E., Dhumeaux D., Kean K.M., and Pawlotsky J.M. Quasispecies heterogeneity and constraints on the evolution of the 5′ noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology 298 (2002) 160-173
43. Tallet-Lopez B., Aldaz-Carroll L., Chabas S., Dausse E., Staedel C., and Toulmé J.J. Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation. Nucleic Acids Res. 31 (2003) 734-742
44. Thelu M.A., Drouet E., Hilleret M.N., and Zarski J.P. Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus. J. Med. Virol. 72 (2004) 396-405
45. Tsukiyama-Kohara K., Iizuka N., Kohara M., and Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66 (1992) 1476-1483
46. Vidalin O., Major M.E., Rayner B., Imbach J.L., Trépo C., and Inchauspé G. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrob. Agents Chemother. 40 (1996) 2337-2344
47. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Kräusslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11 (2005) 791-796
48. Wakita T., and Wands J.R. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J. Biol. Chem. 269 (1994) 14205-14210
49. Zhang H., Hanecak R., Brown-Driver V., Azad R., Conklin B., Fox M.C., and Anderson K.P. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother. 43 (1999) 347-353
50. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., and Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9294-9299